Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the ...

Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

5 Patients were eligible for inclusion in PEACE-3 if they had mCRPC and bone metastases, were asymptomatic or mildly symptomatic, had a WHO performance status of 0 or 1, had not received prior ...

Johnson & Johnson’s (NYSE:JNJ) is the producer of some top-selling drugs which include Stelaera, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, and Opsumit. In the second ...

We recently compiled a list of the 10 Best Defensive Stocks According to Reddit. In this article, we will look at where Johnson & Johnson (NYSE:JNJ) stands against the other defensive stocks.

Johnson & Johnson’s (NYSE:JNJ) top-selling drugs include Stelaera, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, and Opsumit. In the second quarter of 2024, the company ...

Its growth is being driven by existing products like Darzalex, Stelara, Tremfya, Uptravi and Erleada and also continued uptake of new launches, including Spravato, Carvykti and Tecvayli.